Skip to main content
Log in

Insulin-like Growth Factors and Prostate Cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Converging data from epidemiological and biological research implicate insulin-like growth factor (IGF) physiology in the regulation of prostate epithelial cell proliferation and in the pathophysiology of prostate cancer. This review (1)outlines elements of IGF physiology, (2) reviews recent evidence that circulating IGF-I level is related to risk of prostate cancer, (3) provides a hypothesis concerning the biological basis for the relationship between IGF-1 level and risk of prostate cancer, (4) discusses IGF-I physiology in the context of neoplastic progression of prostate cancer, and (5) discusses clinical implications of these lines of research with respect to prevention and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995

    Article  PubMed  Google Scholar 

  2. Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like orowth factors. Endo Rev 15: 80-101, 1994

    Article  Google Scholar 

  3. Juul A, Bang P, Hertel N, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE: Serum insulin-like growth factor I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78: 744-752, 1994

    Article  PubMed  Google Scholar 

  4. Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. JNCI 82:1693-1697, 1990

    PubMed  Google Scholar 

  5. Huynh HT, Tetenes E, Wallace L, Pollak M: In vivoinhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res. 53: 1727-1730, 1993

    PubMed  Google Scholar 

  6. Huynh HT, Yang XF, Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016-1021, 1996

    Article  PubMed  Google Scholar 

  7. Kulik G, Weber MJ: Akt-dependent and independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 11: 6711-6718, 1998

    Google Scholar 

  8. Parrizas M, Saltiel AR, LeRoith D: Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272: 154-161, 1997

    Article  PubMed  Google Scholar 

  9. LeRoith D, Werner H, Beitner-Johnson D, Roberts C: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16: 143-163, 1995

    Article  PubMed  Google Scholar 

  10. Yang XF, Beamer W, Huynh HT, Pollak M: Reduced growth of human breast cancer xenografts in hosts homozygous for the ‘lit’mutation. Cancer Res 56: 1509-1511, 1996

    PubMed  Google Scholar 

  11. Cohen P, Peehl DM, Lamson G, Rosenfeld RG: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73: 401-407, 1991

    PubMed  Google Scholar 

  12. Cohen P, Peehl DM, Rosenfeld RG: The IGF axis in the prostate. Horm Metab Res 26: 81-84, 1994

    PubMed  Google Scholar 

  13. Chan JM, Stampfer MK, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998

    Article  PubMed  Google Scholar 

  14. Wolk A, Mantzoros CS, Andersson S-O, Bergstrom R, Signorello LB, Lagiou P, Adami H-O, Trichopoulos D: Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. JNCI 90: 911-915, 1998

    PubMed  Google Scholar 

  15. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76: 1115-1118, 1997

    PubMed  Google Scholar 

  16. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE: The ratio between serum levels of Insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP)-1, 2 and 3 decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol 41: 85-93, 1994

    Google Scholar 

  17. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998

    Article  PubMed  Google Scholar 

  18. Pollak M, Ma J, Giovannucci E, Platz EA, Majeed N, Tao Y, Chan J, Hennekens CH, Colditz GA, Speizer F, Willett W, Hankinson S, Stampfer MJ: Circulating levels of IGF-I and IGFBP-3 are related to risk of colorectal cancer. Submitted, 1998

  19. Pollak M, JazmajiV, Jenkins D, Marcon N, Saibil F, Stern H, Baron D, Majeed N, Tao Y, McKeown-Eyssen GE: Relationship of colorectal cancer risk to serum insulin-like growth factor I and insulin-like growth factor binding protein 3. Submitted, 1998

  20. Cohen SM Ellwein LB: Genetic Errors, Cell Proliferation, and Carcinogenesis. Cancer Res 51: 6493-6505, 1991

    PubMed  Google Scholar 

  21. Cohen SM Ellwein LB: Cell proliferation in carcinogenesis. Science 249: 1007-1011, 1990

    PubMed  Google Scholar 

  22. Preston-Martin S, Pike MC, Ross RK, Henderson BE: Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ Health Persp 101: 137-138, 1993

    Google Scholar 

  23. Butterworth BE, Goldsworthy TL: The role of cell proliferation in multistage carcinogenesis. PSEBM 198: 683-687, 1991

    Google Scholar 

  24. Cohen SM: Role of cell proliferation in regenerative and neoplastic disease. [Review] [20 refs]. Toxicol Let 82-83: 15-21, 1995

    Article  Google Scholar 

  25. Rosen C, Pollak M: Circulating IGF-I: a new prospective for a new century. Trends in endocrinology and metabolism, (In press)

  26. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP: Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. iJ Clin Endocrinol Metab 83: 2286-2290, 1998

    Article  Google Scholar 

  27. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW: Gene expression profiles in normal and cancer cells. Science 276: 1268-1272, 1997

    Article  PubMed  Google Scholar 

  28. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP: Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nature Medicine 4: 1276-1280, 1998

    Article  PubMed  Google Scholar 

  29. Cohen P, Graves CB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG: Prostate-specific antigen (PSA) is an Insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endo Met 75: 1046-1053, 1992

    Article  Google Scholar 

  30. Nickerson T, Pollak M, Huynh H: Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinol 139: 807-810, 1998

    Article  Google Scholar 

  31. Nickerson T, Pollak M: Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Submitted, 1998

  32. Nickerson T, Huynh H: Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endo, (In press)

  33. Rozen F, Yang X, Huynh HT, Pollak M: Antiproliferative action of vitamin-D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 89: 652-656, 1997

    Article  PubMed  Google Scholar 

  34. Pollak M, Schally AV: Mechanism of antineoplastic action of somatostatin analogues. Proc Soc Exp Bio Med 217: 143-152, 1998

    Google Scholar 

  35. http://cancernet.nci.nih.gov/cgi-bin/cancerphy show?fileDpro12541.html. 1998

  36. http://cancernet.nci.nih.gov/cgi-bin/cancerphy show?fileDpro12166.html. 1998

  37. Lamharzi N, Schally AV, Koppan M, Groot K: Growth hormone-releasing antagonist Mz-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumours. Proc Natl Acad Sci USA 95: 8864-8868, 1998

    Article  PubMed  Google Scholar 

  38. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252, 1995

    PubMed  Google Scholar 

  39. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332: F105-F126, 1997

    Article  PubMed  Google Scholar 

  40. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998

    PubMed  Google Scholar 

  41. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998

    PubMed  Google Scholar 

  42. Slamon DJ, Leyland-Jones B, Shak S et al.: Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2C=MBC) markedly increases anticancer activity: A randomized, mutlinational controlled phase III trial. Proc Am Soc Clin Oncology 17: 1998 (Abstract)

  43. Barinaga M: Study suggests new way to gauge prostate cancer risk. Science 279: 475, 1998

    Article  PubMed  Google Scholar 

  44. Thompson IM, Coltman CAJ, Crowley J: Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate 33: 217-221, 1997

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pollak, M., Beamer, W. & Zhang, JC. Insulin-like Growth Factors and Prostate Cancer. Cancer Metastasis Rev 17, 383–390 (1998). https://doi.org/10.1023/A:1006154108619

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006154108619

Navigation